Biote, Bio-Techne Beat Q1 Estimates; Ekso Lags

Biote Corp reported strong Q1 results, beating earnings estimates by $0.23 per share and exceeding revenue expectations, though its stock is down significantly year-over-year. Bio-Techne also beat earnings estimates by $0.05 but narrowly missed revenue targets, with shares declining over the past year. In contrast, Ekso Bionics missed both EPS and revenue estimates for Q1 2025 and has not surpassed analyst expectations in the last four quarters, with its stock dropping by more than 60% year-on-year. Financial health ratings from InvestingPro gave 'good performance' scores to Biote Corp and Bio-Techne, while Ekso Bionics was rated as 'fair performance.' The sector overall is experiencing mixed earnings results and broad stock price declines. Investors are advised to watch for future earnings estimate revisions and management commentary for guidance.